[go: up one dir, main page]

MX2007002397A - Nuevas composiciones farmaceuticas que comprenden acido 4-(4-(3-(4-cloro-3-trifluorometil-fenil)-ureido)-3-fluoro-fenoxi) -piridina-2-carboxilico para el tratamiento de desordenes hiper-proliferativos. - Google Patents

Nuevas composiciones farmaceuticas que comprenden acido 4-(4-(3-(4-cloro-3-trifluorometil-fenil)-ureido)-3-fluoro-fenoxi) -piridina-2-carboxilico para el tratamiento de desordenes hiper-proliferativos.

Info

Publication number
MX2007002397A
MX2007002397A MX2007002397A MX2007002397A MX2007002397A MX 2007002397 A MX2007002397 A MX 2007002397A MX 2007002397 A MX2007002397 A MX 2007002397A MX 2007002397 A MX2007002397 A MX 2007002397A MX 2007002397 A MX2007002397 A MX 2007002397A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
hyper
proliferative disorders
ureido
phenoxy
Prior art date
Application number
MX2007002397A
Other languages
English (en)
Inventor
Jacques Dumas
Paul Ehrilich
Susanne Zuleger
Original Assignee
Bayer Pharmaceuticals Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35517032&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2007002397(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Pharmaceuticals Corp filed Critical Bayer Pharmaceuticals Corp
Publication of MX2007002397A publication Critical patent/MX2007002397A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)

Abstract

Esta invencion se refiere a nuevas composiciones farmaceuticas que comprenden una dispersion solida del compuesto de la Formula (I), a procesos para preparar estas nuevas composiciones farmaceuticas y a su para tratar los desordenes hiper-proliferativos, tal como cancer, ya sea como un agente unico o en combinacion con otras terapias.
MX2007002397A 2004-08-27 2005-08-29 Nuevas composiciones farmaceuticas que comprenden acido 4-(4-(3-(4-cloro-3-trifluorometil-fenil)-ureido)-3-fluoro-fenoxi) -piridina-2-carboxilico para el tratamiento de desordenes hiper-proliferativos. MX2007002397A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60475204P 2004-08-27 2004-08-27
PCT/US2005/030541 WO2006026500A1 (en) 2004-08-27 2005-08-29 New pharmaceutical compositions comprising 4-(4-(3-(4-chloro-3-trifluoromethyl-phenyl)-ureido)-3-fluoro-phenoxy)-pyridine-2-carboxylic acid for the treatment of hyper-proliferative disorders

Publications (1)

Publication Number Publication Date
MX2007002397A true MX2007002397A (es) 2007-05-15

Family

ID=35517032

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007002397A MX2007002397A (es) 2004-08-27 2005-08-29 Nuevas composiciones farmaceuticas que comprenden acido 4-(4-(3-(4-cloro-3-trifluorometil-fenil)-ureido)-3-fluoro-fenoxi) -piridina-2-carboxilico para el tratamiento de desordenes hiper-proliferativos.

Country Status (41)

Country Link
US (2) US20060058358A1 (es)
EP (2) EP2589384A1 (es)
JP (1) JP5017115B2 (es)
KR (1) KR101336737B1 (es)
CN (2) CN101287463A (es)
AR (1) AR050616A1 (es)
AU (1) AU2005279996A1 (es)
BR (1) BRPI0514715B1 (es)
CA (1) CA2578438C (es)
CL (1) CL2010001484A1 (es)
CR (1) CR8980A (es)
CY (1) CY2017038I2 (es)
DK (1) DK1793824T3 (es)
EA (1) EA010832B1 (es)
EC (1) ECSP077299A (es)
ES (1) ES2561618T3 (es)
GT (1) GT200500230A (es)
HN (1) HN2005000484A (es)
HR (1) HRP20160156T1 (es)
HU (2) HUE026654T2 (es)
IL (1) IL181590A (es)
LT (1) LTC1793824I2 (es)
LU (1) LUC00047I2 (es)
MA (1) MA28911B1 (es)
ME (2) MEP35808A (es)
MX (1) MX2007002397A (es)
MY (1) MY191349A (es)
NI (1) NI200700064A (es)
NO (2) NO343937B1 (es)
NZ (1) NZ553557A (es)
PE (2) PE20060505A1 (es)
PL (1) PL1793824T3 (es)
PT (1) PT1793824E (es)
RS (1) RS54580B1 (es)
SI (1) SI1793824T1 (es)
TN (1) TNSN07076A1 (es)
TW (1) TWI369987B (es)
UA (1) UA92472C2 (es)
UY (1) UY29086A1 (es)
WO (1) WO2006026500A1 (es)
ZA (1) ZA200702392B (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
ATE538794T1 (de) * 1999-01-13 2012-01-15 Bayer Healthcare Llc Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
US7371763B2 (en) * 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
MY169670A (en) 2003-09-03 2019-05-08 Tibotec Pharm Ltd Combinations of a pyrimidine containing nnrti with rt inhibitors
US20080108672A1 (en) * 2002-01-11 2008-05-08 Bernd Riedl Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
SI1478358T1 (sl) 2002-02-11 2013-09-30 Bayer Healthcare Llc Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
US7557129B2 (en) * 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
EP1626714B1 (en) * 2003-05-20 2007-07-04 Bayer Pharmaceuticals Corporation Diaryl ureas for diseases mediated by pdgfr
EP1663978B1 (en) * 2003-07-23 2007-11-28 Bayer Pharmaceuticals Corporation Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
BRPI0515946A (pt) * 2004-09-29 2008-08-12 Bayer Healthcare Ag sal de tosilato, sua preparação e uso, bem como composição farmacêutica compreendendo o mesmo
CA2601955C (en) * 2005-03-07 2012-07-10 Bayer Healthcare Ag Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
US20090074917A2 (en) * 2006-07-26 2009-03-19 Remington Direct Lp Low-calorie, no laxation bulking system
US20080026038A1 (en) * 2006-07-26 2008-01-31 Remington Direct Lp No laxation, low flatulence bulking system
BRPI0719883A2 (pt) 2006-10-09 2015-05-05 Takeda Pharmaceutical Inibidores de quinase
AR062927A1 (es) * 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
EP1920767A1 (en) * 2006-11-09 2008-05-14 Abbott GmbH & Co. KG Melt-processed imatinib dosage form
EP2089003A1 (en) * 2006-11-09 2009-08-19 Abbott GmbH & Co. KG Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor
TWI494133B (zh) * 2007-03-14 2015-08-01 Tibotec Pharm Ltd 重組用粉末
CA2686756A1 (en) * 2007-05-11 2008-11-20 F. Hoffmann-La Roche Ag Pharmaceutical compositions for poorly soluble drugs
WO2009114703A2 (en) * 2008-03-12 2009-09-17 Fox Chase Cancer Center Combination therapy for the treatment of cancer
UA107186C2 (xx) * 2008-12-03 2014-12-10 Тверді форми дозування бендамустину
WO2010068951A1 (en) * 2008-12-12 2010-06-17 Fox Chase Cancer Center Combination therapy based on src and aurora kinase inhibition for the treatment of cancer
JO3112B1 (ar) * 2010-03-29 2017-09-20 Ferring Bv تركيبة دوائية سريعة التحلل
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
PH12012502432A1 (en) * 2010-06-09 2013-02-11 Abbvie Inc Solid dispersions containing kinase inhibitors
SMT202000390T1 (it) 2010-07-12 2020-09-10 Salix Pharmaceuticals Inc Formulazioni di rifaximina e loro usi
CA2805874A1 (en) 2010-07-19 2012-01-26 Bayer Healthcare Llc Drug combinations with fluoro-substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
EP2621486A1 (en) 2010-10-01 2013-08-07 Bayer Intellectual Property GmbH Substituted n-(2-arylamino)aryl sulfonamide-containing combinations
EP2632436B1 (en) 2010-10-29 2018-08-29 Abbvie Inc. Solid dispersions containing an apoptosis-inducing agent
UA113500C2 (xx) * 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
CN103301066B (zh) * 2012-03-15 2018-12-07 苏州泽璟生物制药有限公司 一种改善吸收性能的固体分散体及其制备
AR092439A1 (es) * 2012-09-06 2015-04-22 Bayer Healthcare Llc Composicion farmaceutica recubierta que contiene regorafenib
US9211290B2 (en) * 2012-12-31 2015-12-15 Noven Therapeutics, Llc Solid dispersions of amorphous paroxetine mesylate
IN2013CH04511A (es) * 2013-10-04 2015-04-10 Hetero Research Foundation
CN104721142B (zh) * 2013-12-18 2020-04-28 山东新时代药业有限公司 一种利伐沙班固体分散体及其制备方法
WO2016005874A1 (en) * 2014-07-09 2016-01-14 Shilpa Medicare Limited Process for the preparation of regorafenib and its crystalline forms
CN105267167A (zh) * 2015-09-11 2016-01-27 江苏嘉逸医药有限公司 一种瑞戈非尼口服固体药物组合物的制备方法
CN105330600B (zh) * 2015-11-30 2018-05-22 山东罗欣药业集团股份有限公司 一种瑞戈菲尼的制备方法
CN105879049B (zh) * 2016-05-13 2019-03-26 浙江大学 一种瑞戈非尼与β-环糊精的包合物及其制备方法
CN107661296A (zh) * 2016-07-27 2018-02-06 江苏先声药业有限公司 一种瑞戈非尼固体分散体及其制备方法
CN110072525B (zh) 2016-09-30 2022-12-02 萨利克斯药品公司 利福昔明的固态分散形式
CN111166724A (zh) * 2018-11-09 2020-05-19 北京化工大学 一种瑞戈非尼纳米分散体、片剂及其制备方法
EP3861989A1 (en) 2020-02-07 2021-08-11 Bayer Aktiengesellschaft Pharmaceutical composition containing regorafenib and a stabilizing agent
US20230119355A1 (en) * 2020-03-05 2023-04-20 Aurigene Discovery Technologies Limited Pharmaceutical compositions of a kinase inhibitor
CN112587485A (zh) * 2021-01-08 2021-04-02 湖南南新制药股份有限公司 一种药物固体分散体及其制备方法
CN112842998A (zh) * 2021-01-19 2021-05-28 深圳市简一生物科技有限公司 一种瑞戈非尼分散剂及其制备方法
FR3123358B1 (fr) 2021-05-25 2024-05-10 Vecormat Bfc Procédé d’élaboration d’un matériau naturel composite à faible emprunte carbone et fort taux de matière naturelle.
WO2022253945A1 (en) 2021-06-04 2022-12-08 Bayer Aktiengesellschaft Pharmaceutical dosage forms comprising 3-(5-methyl-1,3-thiazol-2-yl)-5-[(3r)-tetrahydrofuran-3-yloxy]-n-{(1r)-1-[2-(trifluoromethyl)pyrimidin-5-yl]ethyl}-benzamide
CN114767633B (zh) * 2022-04-07 2023-03-31 郑州大学第一附属医院 含抗乳腺癌药物他莫昔芬的固体分散体、制备方法及制剂
WO2025242583A1 (en) 2024-05-24 2025-11-27 Bayer Consumer Care Ag Novel formulation comprising elinzanetant in a solid dispersion

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4151273A (en) * 1974-10-31 1979-04-24 The Regents Of The University Of California Increasing the absorption rate of insoluble drugs
US4220302A (en) 1978-07-21 1980-09-02 Hampton Diane M Nursing bottle holder
ES2111065T5 (es) * 1991-04-16 2005-06-16 Nippon Shinyaku Company, Limited Procedimiento para producir una dispersion solida.
DK1047418T3 (da) * 1997-12-22 2005-11-21 Bayer Pharmaceuticals Corp Inhibering af raf-kinase ved hjælp af substituerede heterocykliske urinstoffer
RU2265597C2 (ru) * 1997-12-22 2005-12-10 Байер Копэрейшн Арил- и гетероарилзамещенные гетероциклические производные мочевины, способ ингибирования киназы raf и фармацевтическая композиция
CN1213022C (zh) * 1997-12-22 2005-08-03 拜尔有限公司 用对称和不对称的取代二苯脲抑制raf激酶
US7928239B2 (en) 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
ATE538794T1 (de) * 1999-01-13 2012-01-15 Bayer Healthcare Llc Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
HU225780B1 (en) * 1999-01-13 2007-08-28 Bayer Corp Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors and phareutical compositions containing them
EP1140840B1 (en) 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
JP3789066B2 (ja) 1999-12-08 2006-06-21 三菱電機株式会社 液晶表示装置
BR0110310A (pt) * 2000-04-19 2003-02-18 Fujisawa Pharmaceutical Co Dispersão sólida, processo para sua produção e preparado farmacêutico contendo a mesma
US8725620B2 (en) 2000-07-10 2014-05-13 Nobuyoshi Morimoto System and method for negotiating improved terms for products and services being purchased through the internet
WO2002013792A1 (fr) * 2000-08-11 2002-02-21 Eisai Co., Ltd. Dispersion solide médicamenteuse à solubilité accrue
US20040058956A1 (en) 2000-12-11 2004-03-25 Yohko Akiyama Pharmaceutical composition having an improved water solubility
US7235576B1 (en) * 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
CA2434835A1 (en) * 2001-02-13 2002-08-22 Astrazeneca Ab Novel modified released formulation
SE0103838D0 (sv) * 2001-11-16 2001-11-16 Astrazeneca Ab Pharmaceutical formulation & product
EP1578346A4 (en) * 2001-12-04 2007-11-28 Onyx Pharma Inc INHIBITORS OF THE RAF-MEK-ERK PATHWAY TO TREAT CANCER
US20030207872A1 (en) * 2002-01-11 2003-11-06 Bayer Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
RU2004123621A (ru) * 2002-02-01 2005-04-10 Пфайзер Продактс Инк. (Us) Лекарственные формы с немедленным высвобождением, содержащие твердые дисперсии лекарств
SI1478358T1 (sl) * 2002-02-11 2013-09-30 Bayer Healthcare Llc Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
CA2430180C (en) 2003-05-21 2010-03-16 Royal Group Technologies Limited Cascade shade
EP1663978B1 (en) * 2003-07-23 2007-11-28 Bayer Pharmaceuticals Corporation Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
CN101048140B (zh) * 2004-08-27 2013-06-19 拜尔保健公司 用于治疗癌症的药物组合物

Also Published As

Publication number Publication date
KR101336737B1 (ko) 2013-12-04
HUS1700047I1 (hu) 2017-12-28
NO20071584L (no) 2007-05-24
CA2578438C (en) 2015-10-06
US20060058358A1 (en) 2006-03-16
JP2008511685A (ja) 2008-04-17
PE20100432A1 (es) 2010-07-21
IL181590A (en) 2013-04-30
CA2578438A1 (en) 2006-03-09
UA92472C2 (ru) 2010-11-10
DK1793824T3 (en) 2016-02-01
EA200700501A1 (ru) 2007-08-31
LUC00047I2 (es) 2018-01-10
CL2010001484A1 (es) 2011-04-25
NO343937B1 (no) 2019-07-15
LUC00047I1 (es) 2017-11-15
PE20060505A1 (es) 2006-06-18
PL1793824T3 (pl) 2016-06-30
TW200616627A (en) 2006-06-01
ECSP077299A (es) 2007-04-26
NO2019033I1 (no) 2019-08-05
US20170165243A1 (en) 2017-06-15
HN2005000484A (es) 2010-06-08
ZA200702392B (en) 2008-11-26
EP2589384A1 (en) 2013-05-08
SI1793824T1 (sl) 2016-03-31
RS54580B1 (sr) 2016-06-30
KR20070067104A (ko) 2007-06-27
AU2005279996A1 (en) 2006-03-09
EA010832B1 (ru) 2008-12-30
IL181590A0 (en) 2007-07-04
TNSN07076A1 (en) 2008-06-02
CR8980A (es) 2007-10-22
EP1793824B1 (en) 2015-11-18
CN101287463A (zh) 2008-10-15
HRP20160156T1 (hr) 2016-03-11
LTC1793824I2 (lt) 2017-06-12
CN102885813A (zh) 2013-01-23
GT200500230A (es) 2006-03-28
BRPI0514715A (pt) 2008-06-24
AR050616A1 (es) 2006-11-08
BRPI0514715B1 (pt) 2021-11-03
ES2561618T3 (es) 2016-02-29
UY29086A1 (es) 2006-03-31
ME00152B (me) 2010-10-10
MEP35808A (en) 2010-06-10
JP5017115B2 (ja) 2012-09-05
NZ553557A (en) 2010-08-27
MY191349A (en) 2022-06-17
MA28911B1 (fr) 2007-10-01
WO2006026500A1 (en) 2006-03-09
NI200700064A (es) 2008-03-03
CY2017038I1 (el) 2018-06-27
HUE026654T2 (en) 2016-07-28
EP1793824A1 (en) 2007-06-13
PT1793824E (pt) 2016-03-11
TWI369987B (en) 2012-08-11
CY2017038I2 (el) 2018-06-27

Similar Documents

Publication Publication Date Title
MX2007002397A (es) Nuevas composiciones farmaceuticas que comprenden acido 4-(4-(3-(4-cloro-3-trifluorometil-fenil)-ureido)-3-fluoro-fenoxi) -piridina-2-carboxilico para el tratamiento de desordenes hiper-proliferativos.
WO2004078747A8 (en) Novel cyanopyridine derivatives useful in the treatment of cancer and other disorders
MXPA05010712A (es) Derivados de quinolin-2-ona para el tratamiento de enfermedades de las vias respiratorias.
IL187328A (en) N- Methyl-2-Fluoro- {4- [3- (4-Cyano-3-Trifluoromethylphenyl) -5,5-Dimethyl-4-Oxo-2-Theoxo-Imidazolidin-1-Ill]} Benzamide, Pharmaceuticals Containing It and its use for drug preparation
WO2007064931A3 (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
MXPA05010682A (es) Compuestos novedosos.
TW200738724A (en) Substituted 4-amino-pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
TW200608979A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
MX2007002398A (es) Nuevas composiciones farmaceuticas para el tratamiento de cancer.
SE0301009D0 (sv) Novel compounds
WO2004078746A3 (en) 2-oxo-1,3,5-perhydrotriazapine derivatives useful in the treatment of hyper-proliferative, angiogenesis, and inflammatrory disorders
NO20071577L (no) Bifenyloksyiddiksyrederivater for behandling av luftveissykdommer
TW200630336A (en) Novel compounds
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
TW200745003A (en) Novel compounds
WO2007076085A3 (en) Fused pyrimidones and thiopyrimidones, and uses thereof
WO2007129066A8 (en) 4- (2,6-dichloro-benzoylamino) -1h-pyrazole-3-carboxylic acid (1-methanesulphonyl-piperidin-4-yl) -amide for the treatment of cancer
TW200733961A (en) Diaryl urea for treating pulmonary hypertension
TW200745081A (en) Compounds
WO2007076087A3 (en) 3-aryl-substituted quinazolones, and uses thereof
IL176914A0 (en) Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, method for the production thereof and their use as medicaments
MX2009005242A (es) Derivados de 3-(hetero)arilisoquinolinamida sustituida en posición 5, 6 o 7 y uso terapeutico del mismo.
NO20063859L (no) Cykloalkylsubstituerte 7-amino-4-kinolon-3-karboksylsyrederivater, fremgangsmate for fremstilling derav og anvendelse derav som medikamenter
WO2005102997A8 (en) 3,4-disubstituted maleimides for use as vascular damaging agents
WO2007054303A3 (en) Diaryl urea for treating diabetic neuropathy

Legal Events

Date Code Title Description
GB Transfer or rights
FG Grant or registration